MedTrace Logo

Proteomic Study of Tears From Patients With a PAX6 Mutation

NCT05562115 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-08-09

No results posted yet for this study

Summary

This is a single-center prospective pilot study involving the ophthalmology and medical genetics departments of the Montpellier University Hospital, and the proteomics platform of the Montpellier University Hospital.

5 patients with PAX6 pathogenic variation will be included in order to determine the proteomic profile in a tear sample associated with different pathogenic variations of the PAX6 gene.

Participation in the study for the patients consists of a single visit with an ophthalmological examination and a tear collection.

Conditions

  • Aniridia

Interventions

OTHER

Tear collection

Collection of tears by Schirmer strip (2 to 4 mm).

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Marjolaine WILLEMS, PH · University Hospital, Montpellier

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2023-11-22
Completion
2023-11-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562115 on ClinicalTrials.gov